FOCUS: ONCOLOGY
Landmark mRNA cancer vaccine trial paves way for FDA clearance
For years, scientists have been exploring the use of mRNA drugs to treat cancer, and now – for the first time – an experimental drug to deliver a vaccine customised to a patient’s tumours has passed a large phase 3 clinical trial, effectively clearing melanoma recurrence.
This opens the door for the Food and Drug Administration to potentially approve the first mRNA-based cancer treatment in what would be a landmark moment for the fast-emerging field, reports The Washington Post.
Some experts...

